A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
Completed · Phase 1
Conditions studied: Medulloblastoma, Pontine Glioma, Ependymoma, Astrocytoma, PNET
In brief
Background: \- An experimental drug called ABT-888 has been studied in combination with temozolomide (a type of chemotherapy) in adults who have certain kinds of cancer. ABT-88 has been shown to increase tumor sensitivity to temozolomide and improve treatment outcomes in people who have cancer. More research is needed to determine if this combination of drugs will work well as an effective treatment for children who have brain tumors. This will be the first time this combination has been studied in pediatric patients. Objectives: * To determine the maximum doses of ABT-888 and temozolomide when given in combination in children with brain tumors. * To learn how children metabolize and clear ABT-888 from their bodies so that appropriate doses of this medication can be recommended for future clinical trials of this drug. * To learn what side effects may occur when ABT-888 and temozolomide are given together. * To learn how certain tumors respond to this combination of drugs by studying the characteristics of these tumors in a laboratory. Eligibility: \- Individuals less than 21 years of age who have been diagnosed with a cancer of the nervous system (including brain and brain stem tumors) that has not responded to standard therapy. Design: * Before beginning the study, participants will have a full medical history and physical examination, and may also be required to have scans of the brain and spine or provide samples of cerebrospinal fluid. * Treatment will consist of up to 13 28-day cycles of therapy, for a total of 52 weeks (1 year). Participants will receive a dose of ABT-888 twice daily for 5 days, and will receive a dose of temozolomide once daily for 5 days, every 28 days. The morning dose of ABT-888 will be given 60-90 minutes before the dose of temozolomide. * Participants will have routine blood tests at least once a week throughout the treatment cycles, and will have scans of the brain and spine performed as required by the researchers.
Key facts
- Study ID
- NCT00994071
- Run by
- National Cancer Institute (NCI)
- People needed
- 9
- Starts
- 2009-09-22
- Expected to finish
- 2013-03-19
- Last updated by the study team
- 2019-12-09
Who can join
Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Concomitant Medications:
- Patients receiving any of the following medications are not eligible for study entry:
- Anti-cancer therapy
- Investigational agents
- Concurrent Illness:
- Patients with any clinically significant, unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that would compromise the patient s ability to tolerate protocol therapy or would likely interfere with the study procedures or results.
- Seizures:
- Patients with uncontrolled seizures are not eligible for study entry.
- Hypertension:
- Patients with inadequately controlled systemic hypertension (SBP and/or DBP greater than 95th percentile for age and height
- Patients with a prior history of hypertensive crisis and/or hypertensive encephalopathy
- If a BP measurement prior to registration is greater than 95th percentile for age and height, it must be rechecked and documented to be less than 95th percentile for age and height prior to registration. If a patient falls between the height or weight percentiles, site should average the value as appropriate. For patients greater than or equal to 18 years the normal blood pressure should be less than 140/90 mm of Hg. Patients with hypertension are eligible if their blood pressures become less than 95th percentile for age and height after anti-hypertensive medications.
- Prior CNS ischemia and/or infarction:
- Patients with documented CNS ischemia and/or infarction, whether symptomatic or discovered incidentally without clinical symptoms, will be excluded from study participation.
- Inability to Participate:
- Patients with an inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
Where it is running
- National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.